Managing Human Immunodeficiency Virus-associated Tuberculosis in the Dolutegravir Era

Gary Maartens^{1

2}, Graeme Meintjes^{2

3}

Affiliations

¹ Division of Clinical Pharmacology, Department of Medicine, South Africa.
² Wellcome Centre for Infectious Diseases Research in Africa, Institute of Infectious Disease and Molecular Medicine, South Africa.
³ Division of Infectious Diseases and Human Immunodeficiency Virus Medicine, Department of Medicine, University of Cape Town, South Africa.

Comment

Gary Maartens et al. Clin Infect Dis. 2020.

. 2020 Feb 3;70(4):557-558.

doi: 10.1093/cid/ciz259.

Gary Maartens^{1

2}, Graeme Meintjes^{2

3}

¹ Division of Clinical Pharmacology, Department of Medicine, South Africa.
² Wellcome Centre for Infectious Diseases Research in Africa, Institute of Infectious Disease and Molecular Medicine, South Africa.
³ Division of Infectious Diseases and Human Immunodeficiency Virus Medicine, Department of Medicine, University of Cape Town, South Africa.

No abstract available

Keywords: dolutegravir; drug-drug interaction; immune reconstitution inflammatory syndrome; rifampicin; tuberculosis.

Comment on

Dolutegravir-based Antiretroviral Therapy for Patients Coinfected With Tuberculosis and Human Immunodeficiency Virus: A Multicenter, Noncomparative, Open-label, Randomized Trial.
Dooley KE, Kaplan R, Mwelase N, Grinsztejn B, Ticona E, Lacerda M, Sued O, Belonosova E, Ait-Khaled M, Angelis K, Brown D, Singh R, Talarico CL, Tenorio AR, Keegan MR, Aboud M; International Study of Patients with HIV on Rifampicin ING study group. Dooley KE, et al. Clin Infect Dis. 2020 Feb 3;70(4):549-556. doi: 10.1093/cid/ciz256. Clin Infect Dis. 2020. PMID: 30918967 Clinical Trial.